Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)

Organization
NIH
Type
NIH
Application or LOI Due Date
02-17-2020
Number
PAR-20-035
Comments
LOI required and due 30 days prior to the application due date. Application Due Date(s) 3/17/20, 7/17/20, 11/17/20, 3/17/21,7/19/21, 11/17/21, 3/17/22, 7/19/22, 11/7/22
Brief Description

This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with an Exploratory/Developmental Phased Award (R61/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R61 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, permitting accelerated bi-directional research exchange.